drugset / Trial / NCT01517360

Pharmacological Approach to Improve the Outcome of Social Cognition Training

NCT01517360

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate whether oxytocin will facilitate the learning of social cognitive skills in schizophrenia patients who receive 12 sessions of Social Cognitive Skills Training (SCST). The primary hypothesis is that schizophrenia subjects who are treated with oxytocin will demonstrate greater improvements in a summary measure of social cognition than subjects treated with placebo over the course of SCST.

Timeline

Start
2012-01
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxytocin Peptide 40 iu Intranasal

Indications